Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Vnitr Lek ; 66(6): 14-18, 2020.
Article in English | MEDLINE | ID: mdl-33380148

ABSTRACT

Hemodialysed patients with end stage renal disease are reliant to proper function of vascular access - mostly arterio-venous fistula (AVF). AVF patency is jeopardized by stenosis formation, which needs to be treated before thrombosis. Angioplasty is primarily indicated and prolongs vascular access patency. High pressure balloons and cutting balloons aid to high technical success rate. Angioplasty needs to be repeated in order to maintain long term patency. Drug-eluting balloons prolong long term patency. Stents and stentgrafts are seldom used in inoperable patients and in selected locations. Technical advances allowed endovascular treatment in AVF thrombosis followed by angioplasty of culprit lesion. Vascular access endovascular occlusion is alternative for surgery in inoperable patients. In patients with residual renal function or iodine allergy, intervention could be ultrasound guided or carbon dioxide could be used without the need of iodine contrast.


Subject(s)
Angioplasty, Balloon , Arteriovenous Shunt, Surgical , Angioplasty , Arteriovenous Shunt, Surgical/adverse effects , Humans , Renal Dialysis , Retrospective Studies , Stents , Treatment Outcome , Vascular Patency
2.
Article in English | MEDLINE | ID: mdl-30198520

ABSTRACT

INTRODUCTION: Hormone changes during pregnancy lead to increased plasma lipid levels. When there is added disorder of lipid metabolism, this otherwise physiological change can cause extremely high triglyceride levels with potentionally life-threatening complications, such as non-biliary acute pancreatitis. MATERIALS AND METHODS: We present a case report of a 27-year-old pregnant woman with familial hyperchylomicronemia and a history of 7 hypertriglyceridemia-induced acute pancreatitis attacks. Three attacks occured during her first pregnancy with the last one leading to its termination at 33 weeks owing to the death of the fetus. During her second pregnancy, standard treatment was not able to lower the triglyceride levels sufficiently and she suffered another acute pancreatitis attack. Therapeutic plasma exchange was therefore chosen as the treatment method. RESULTS AND CONCLUSION: Plasma exchange was succesful in the secondary prevention of acute pancreatitis attack and she delivered a healthy baby at 36 weeks of gestation. Treatment was very well tolerated by the mother and the fetus and this supports the use of apheresis as a safe and efficient method in tackling gestational hypertriglyceridemia.


Subject(s)
Hypertriglyceridemia/prevention & control , Pancreatitis/prevention & control , Plasma Exchange , Pregnancy Complications/therapy , Adult , Female , Humans , Hypertriglyceridemia/blood , Hypertriglyceridemia/therapy , Pancreatitis/blood , Pancreatitis/therapy , Pregnancy , Pregnancy Complications/blood , Pregnancy Outcome , Pregnancy Trimester, Third , Secondary Prevention
3.
Iran J Kidney Dis ; 10(5): 332-335, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27721233

ABSTRACT

Treatment of retroperitoneal fibrosis usually involves corticosteroids with or without other immunomodulating medications or tamoxifen.  Rituximab, a monoclonal antibody that specifically targets CD20 on the surface of B-cells, is effective in achieving complete remission of proteinuria in patients with idiopathic membranous nephropathy. We describe a case of a 45 years old man with idiopathic membranous glomerulonephritis (with proteinuria of more than 30 grams/24 hours) and simultaneously with idiopathic retroperitoneal fibrosis (with large number of cells CD20 in the histologic image). The patient did not tolerate the treatment by cyclophosphamide, and as rescue therapy, administration of rituximab was indicated with excellent effect. We recorded promptreduction of proteinuria and significant reduction of retroperitoneal fibrosis. Rituximab is effective in treatment of idiopathic retroperitonea lfibrosis with positivity of CD20 cells, as well as in treatment of idiopathic membranous glomerulonephritis.


Subject(s)
Glomerulonephritis, Membranous/drug therapy , Immunologic Factors/therapeutic use , Proteinuria/drug therapy , Retroperitoneal Fibrosis/drug therapy , Rituximab/therapeutic use , Glomerulonephritis, Membranous/complications , Humans , Male , Middle Aged , Proteinuria/etiology , Retroperitoneal Fibrosis/complications , Retroperitoneal Fibrosis/diagnostic imaging , Retroperitoneal Fibrosis/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...